 Hitoshi Irabu
Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Juvenile | 9 | 2025 | 58 | 2.030 |
Why?
| | Macrophage Activation Syndrome | 8 | 2025 | 22 | 1.710 |
Why?
| | Lupus Erythematosus, Systemic | 7 | 2026 | 239 | 1.630 |
Why?
| | Glomerulonephritis, IGA | 2 | 2020 | 12 | 1.270 |
Why?
| | Biomarkers | 12 | 2024 | 4275 | 1.060 |
Why?
| | Dermatomyositis | 4 | 2026 | 24 | 0.910 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 6 | 2024 | 91 | 0.760 |
Why?
| | Antirheumatic Agents | 4 | 2025 | 304 | 0.730 |
Why?
| | Osteomyelitis | 1 | 2022 | 143 | 0.650 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2025 | 988 | 0.640 |
Why?
| | Receptors, Scavenger | 1 | 2020 | 22 | 0.640 |
Why?
| | Galactose | 1 | 2020 | 34 | 0.630 |
Why?
| | Galactosemias | 1 | 2020 | 16 | 0.630 |
Why?
| | Immunoglobulin A | 2 | 2023 | 214 | 0.610 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2020 | 187 | 0.600 |
Why?
| | Lupus Nephritis | 3 | 2026 | 70 | 0.590 |
Why?
| | Japan | 6 | 2026 | 143 | 0.570 |
Why?
| | Pyelonephritis | 3 | 2022 | 11 | 0.530 |
Why?
| | Cytokines | 7 | 2025 | 2065 | 0.500 |
Why?
| | Interferon-Induced Helicase, IFIH1 | 3 | 2025 | 19 | 0.490 |
Why?
| | Child | 28 | 2026 | 22657 | 0.450 |
Why?
| | Systemic Inflammatory Response Syndrome | 3 | 2023 | 96 | 0.420 |
Why?
| | Behcet Syndrome | 2 | 2024 | 19 | 0.400 |
Why?
| | Age Factors | 2 | 2020 | 3335 | 0.390 |
Why?
| | Interleukin-18 | 3 | 2024 | 235 | 0.370 |
Why?
| | Takayasu Arteritis | 2 | 2022 | 16 | 0.340 |
Why?
| | Shock, Septic | 2 | 2023 | 216 | 0.340 |
Why?
| | Edema | 3 | 2026 | 124 | 0.310 |
Why?
| | Child, Preschool | 12 | 2025 | 11799 | 0.300 |
Why?
| | Adolescent | 15 | 2026 | 22453 | 0.280 |
Why?
| | Hearing Loss | 2 | 2022 | 247 | 0.280 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 4 | 2021 | 41 | 0.270 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 851 | 0.270 |
Why?
| | Autoimmune Diseases | 2 | 2023 | 463 | 0.270 |
Why?
| | Humans | 43 | 2026 | 144957 | 0.270 |
Why?
| | Rheumatology | 2 | 2026 | 133 | 0.260 |
Why?
| | Female | 29 | 2026 | 78376 | 0.260 |
Why?
| | Infliximab | 2 | 2024 | 108 | 0.250 |
Why?
| | Interferon-alpha | 2 | 2025 | 197 | 0.250 |
Why?
| | Chemokine CXCL9 | 3 | 2023 | 38 | 0.240 |
Why?
| | Drugs, Chinese Herbal | 1 | 2026 | 24 | 0.240 |
Why?
| | Nephrotic Syndrome | 1 | 2026 | 44 | 0.230 |
Why?
| | Odontodysplasia | 1 | 2025 | 1 | 0.230 |
Why?
| | Lupus Erythematosus, Cutaneous | 1 | 2025 | 7 | 0.230 |
Why?
| | Pericardial Effusion | 1 | 2025 | 22 | 0.220 |
Why?
| | Azetidines | 2 | 2025 | 45 | 0.220 |
Why?
| | Gain of Function Mutation | 1 | 2025 | 36 | 0.220 |
Why?
| | Abatacept | 1 | 2024 | 56 | 0.220 |
Why?
| | Autoimmune Diseases of the Nervous System | 1 | 2025 | 31 | 0.220 |
Why?
| | Nephritis, Interstitial | 1 | 2024 | 11 | 0.220 |
Why?
| | Hydroxychloroquine | 1 | 2025 | 63 | 0.220 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2024 | 1217 | 0.220 |
Why?
| | Histiocytic Necrotizing Lymphadenitis | 1 | 2024 | 1 | 0.220 |
Why?
| | Male | 20 | 2026 | 72406 | 0.210 |
Why?
| | Nervous System Malformations | 1 | 2025 | 47 | 0.210 |
Why?
| | Craniofacial Abnormalities | 1 | 2025 | 76 | 0.210 |
Why?
| | Age of Onset | 1 | 2026 | 551 | 0.210 |
Why?
| | Sweet Syndrome | 1 | 2024 | 10 | 0.210 |
Why?
| | Purines | 2 | 2025 | 187 | 0.200 |
Why?
| | ROC Curve | 3 | 2021 | 615 | 0.200 |
Why?
| | Adalimumab | 1 | 2024 | 55 | 0.200 |
Why?
| | Yersinia pseudotuberculosis Infections | 1 | 2023 | 2 | 0.200 |
Why?
| | Skin Diseases | 1 | 2025 | 149 | 0.200 |
Why?
| | Hypertension | 2 | 2022 | 1264 | 0.200 |
Why?
| | Abnormalities, Multiple | 1 | 2025 | 197 | 0.200 |
Why?
| | Neopterin | 2 | 2021 | 13 | 0.190 |
Why?
| | Autoantibodies | 3 | 2025 | 1504 | 0.190 |
Why?
| | Diagnosis, Differential | 3 | 2025 | 1495 | 0.190 |
Why?
| | Interleukin-6 | 3 | 2025 | 780 | 0.190 |
Why?
| | Myositis | 1 | 2023 | 57 | 0.190 |
Why?
| | Amyloidosis | 1 | 2023 | 44 | 0.190 |
Why?
| | Fever of Unknown Origin | 1 | 2022 | 13 | 0.190 |
Why?
| | Piperidines | 1 | 2024 | 217 | 0.180 |
Why?
| | Scleroderma, Systemic | 1 | 2023 | 123 | 0.180 |
Why?
| | Vasculitis | 1 | 2023 | 69 | 0.180 |
Why?
| | Spinal Muscular Atrophies of Childhood | 1 | 2022 | 18 | 0.180 |
Why?
| | Lymph Nodes | 1 | 2024 | 502 | 0.170 |
Why?
| | Connective Tissue Diseases | 1 | 2022 | 84 | 0.170 |
Why?
| | Pyrazoles | 2 | 2025 | 510 | 0.170 |
Why?
| | Sulfonamides | 2 | 2025 | 581 | 0.170 |
Why?
| | Osteochondrodysplasias | 1 | 2021 | 20 | 0.170 |
Why?
| | Dendritic Cells | 1 | 2024 | 499 | 0.160 |
Why?
| | Pyrimidines | 1 | 2024 | 533 | 0.160 |
Why?
| | Aortitis | 1 | 2020 | 10 | 0.160 |
Why?
| | Urine | 1 | 2020 | 62 | 0.160 |
Why?
| | Bone and Bones | 1 | 2022 | 315 | 0.150 |
Why?
| | Interferon-gamma | 2 | 2021 | 784 | 0.150 |
Why?
| | Reference Standards | 1 | 2020 | 178 | 0.150 |
Why?
| | Acute Generalized Exanthematous Pustulosis | 1 | 2019 | 4 | 0.150 |
Why?
| | Ampicillin | 1 | 2019 | 15 | 0.150 |
Why?
| | Fasciitis | 1 | 2019 | 11 | 0.150 |
Why?
| | Phosphoinositide Phospholipase C | 1 | 2019 | 5 | 0.150 |
Why?
| | Rheumatic Diseases | 1 | 2021 | 97 | 0.150 |
Why?
| | Leukocyte Count | 1 | 2020 | 316 | 0.150 |
Why?
| | Kidney Glomerulus | 1 | 2020 | 128 | 0.150 |
Why?
| | Streptococcus pyogenes | 1 | 2019 | 41 | 0.150 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2019 | 43 | 0.150 |
Why?
| | Orthostatic Intolerance | 1 | 2018 | 2 | 0.150 |
Why?
| | Inflammation | 2 | 2020 | 2880 | 0.140 |
Why?
| | Siblings | 1 | 2019 | 195 | 0.140 |
Why?
| | Monitoring, Physiologic | 1 | 2020 | 289 | 0.130 |
Why?
| | Treatment Outcome | 7 | 2026 | 11695 | 0.130 |
Why?
| | Diagnostic Errors | 1 | 2018 | 175 | 0.130 |
Why?
| | Hemolytic-Uremic Syndrome | 1 | 2017 | 15 | 0.130 |
Why?
| | Ferritins | 1 | 2017 | 69 | 0.130 |
Why?
| | Streptococcal Infections | 1 | 2019 | 169 | 0.130 |
Why?
| | Registries | 1 | 2026 | 2385 | 0.130 |
Why?
| | Tachycardia, Ventricular | 1 | 2018 | 181 | 0.120 |
Why?
| | Biopsy | 1 | 2020 | 1077 | 0.120 |
Why?
| | Lung Diseases, Interstitial | 1 | 2023 | 660 | 0.120 |
Why?
| | Chronic Disease | 1 | 2022 | 1813 | 0.120 |
Why?
| | Asparaginase | 1 | 2016 | 30 | 0.120 |
Why?
| | Kidney | 2 | 2024 | 1496 | 0.120 |
Why?
| | Escherichia coli Infections | 1 | 2017 | 129 | 0.120 |
Why?
| | Hypertriglyceridemia | 1 | 2016 | 44 | 0.120 |
Why?
| | Immunohistochemistry | 1 | 2020 | 1718 | 0.120 |
Why?
| | Brain Diseases | 1 | 2017 | 153 | 0.120 |
Why?
| | Pancreatitis | 1 | 2016 | 145 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2118 | 0.110 |
Why?
| | Epilepsy | 1 | 2018 | 387 | 0.100 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 293 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2020 | 3608 | 0.090 |
Why?
| | Macrophages | 1 | 2020 | 1511 | 0.090 |
Why?
| | Infant | 6 | 2024 | 10039 | 0.090 |
Why?
| | Immunoglobulins, Intravenous | 2 | 2023 | 126 | 0.090 |
Why?
| | Apoptosis | 1 | 2020 | 2430 | 0.090 |
Why?
| | Dizziness | 2 | 2022 | 101 | 0.090 |
Why?
| | Prognosis | 1 | 2020 | 4293 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2025 | 535 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2026 | 17101 | 0.080 |
Why?
| | Fever | 2 | 2023 | 312 | 0.080 |
Why?
| | Immunosuppressive Agents | 2 | 2025 | 847 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1915 | 0.070 |
Why?
| | Mutation | 1 | 2019 | 4099 | 0.070 |
Why?
| | Infant, Newborn | 3 | 2025 | 6434 | 0.060 |
Why?
| | Metacarpus | 1 | 2025 | 6 | 0.060 |
Why?
| | Dental Enamel Hypoplasia | 1 | 2025 | 9 | 0.060 |
Why?
| | Etanercept | 1 | 2024 | 60 | 0.050 |
Why?
| | beta 2-Microglobulin | 1 | 2024 | 47 | 0.050 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2024 | 13 | 0.050 |
Why?
| | Prednisolone | 1 | 2024 | 66 | 0.050 |
Why?
| | Muscular Diseases | 1 | 2025 | 108 | 0.050 |
Why?
| | Methotrexate | 1 | 2025 | 240 | 0.050 |
Why?
| | Heterozygote | 1 | 2025 | 315 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2024 | 120 | 0.050 |
Why?
| | Interferon Type I | 1 | 2025 | 145 | 0.050 |
Why?
| | Aortic Diseases | 1 | 2025 | 124 | 0.050 |
Why?
| | Vascular Calcification | 1 | 2025 | 110 | 0.050 |
Why?
| | Haploinsufficiency | 1 | 2023 | 55 | 0.050 |
Why?
| | Adult | 5 | 2026 | 40506 | 0.050 |
Why?
| | Exanthema | 1 | 2023 | 84 | 0.050 |
Why?
| | Lymphoma | 1 | 2024 | 233 | 0.050 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2023 | 93 | 0.050 |
Why?
| | Chromosome Deletion | 1 | 2023 | 124 | 0.050 |
Why?
| | Chromosomes | 1 | 2023 | 108 | 0.050 |
Why?
| | Osteoporosis | 1 | 2025 | 236 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 331 | 0.040 |
Why?
| | Ultrasonography, Doppler | 1 | 2022 | 126 | 0.040 |
Why?
| | Macrophage Activation | 1 | 2023 | 193 | 0.040 |
Why?
| | Young Adult | 3 | 2024 | 14126 | 0.040 |
Why?
| | Pyuria | 1 | 2020 | 5 | 0.040 |
Why?
| | Bacteriuria | 1 | 2020 | 12 | 0.040 |
Why?
| | Cervical Vertebrae | 1 | 2022 | 158 | 0.040 |
Why?
| | Anti-Inflammatory Agents | 1 | 2024 | 475 | 0.040 |
Why?
| | Intestines | 1 | 2023 | 358 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2020 | 117 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2022 | 3869 | 0.040 |
Why?
| | Genetic Markers | 1 | 2019 | 331 | 0.030 |
Why?
| | Ultrasonography | 1 | 2022 | 770 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1721 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2020 | 417 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2024 | 970 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 917 | 0.030 |
Why?
| | Enterohemorrhagic Escherichia coli | 1 | 2017 | 2 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2023 | 1129 | 0.030 |
Why?
| | Aorta, Thoracic | 1 | 2020 | 286 | 0.030 |
Why?
| | Acute Disease | 1 | 2020 | 1031 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2017 | 81 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2016 | 528 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2852 | 0.020 |
Why?
| | Middle Aged | 2 | 2024 | 35928 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5417 | 0.020 |
Why?
| | Aged | 1 | 2023 | 25947 | 0.010 |
Why?
|
|
Irabu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|